F9

F9 Full Name

coagulation factor IX

F9 Introduction

Coagulation factor IX (F9) is a vitamin K–dependent serine protease that plays a central role in the intrinsic pathway of blood coagulation. Encoded by the F9 gene located on the X chromosome, factor IX is primarily synthesized in the liver and circulates in plasma as an inactive zymogen. When vascular injury occurs, factor IX is activated to factor IXa, which interacts with factor VIIIa on phospholipid surfaces to form the tenase complex, a key enzymatic assembly responsible for converting factor X to factor Xa and ultimately generating thrombin and fibrin for stable clot formation. Because of its critical position in the coagulation cascade, even small changes in factor IX activity can significantly affect hemostasis. Researchers and clinicians have long focused on F9 as an essential therapeutic target, particularly when attempting to address uncontrolled bleeding or coagulation deficiencies that dramatically impact patients' quality of life and long-term health outcomes.

Beyond its physiological role in coagulation, F9 has become a major focus of modern biomedical research due to its direct association with hemophilia B, a hereditary bleeding disorder caused by mutations in the F9 gene. Patients with hemophilia B experience reduced or absent factor IX activity, leading to spontaneous bleeding, prolonged bleeding after injury, and progressive joint damage caused by repeated hemarthrosis. Traditional treatments rely on frequent intravenous infusion of recombinant or plasma-derived factor IX, which can be burdensome and costly for patients. In response to these challenges, research has increasingly explored genetic and molecular strategies aimed at restoring functional factor IX expression. Advanced genome engineering technologies have enabled the creation of large-animal disease models, including CRISPR/Cas9-engineered pigs carrying human F9 sequences. These models reproduce many clinical features of hemophilia B and have demonstrated that targeted correction or replacement of the F9 gene can significantly alleviate bleeding phenotypes, offering researchers a powerful platform for evaluating next-generation therapies.

In recent years, F9 has also become one of the most successful targets for gene therapy development. Adeno-associated virus (AAV)–based gene delivery systems have been designed to introduce functional F9 variants into hepatocytes, enabling long-term endogenous production of factor IX. Clinical studies have shown that therapies incorporating high-activity variants such as the factor IX Padua mutation (R338L) can achieve sustained increases in circulating factor IX activity and dramatically reduce bleeding episodes in adult patients with hemophilia B. These advances highlight the growing clinical potential of precision genetic medicine, where optimized factor IX variants and improved viral vectors can provide durable therapeutic benefit with a single administration. As gene editing, vector engineering, and protein optimization technologies continue to evolve, F9 remains a highly valuable therapeutic target for both translational research and clinical innovation aimed at transforming the treatment landscape of hereditary bleeding disorders.

Alternate Names for F9

F9; coagulation factor IX; FIX; P19; PTC; HEMB; THPH8; F9 p22; FIX F9; factor 9; factor IX F9; Christmas factor; plasma thromboplastic component; plasma thromboplastin component;

• 1.Cuker A, et al.; BENEGENE-2 Trial Investigators. Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B. N Engl J Med. 2024, 391(12):1108-1118.
  2.Pittman DD, et al.; Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec. Thromb Haemost. 2024, 124(10):912-921.